<DOC>
	<DOCNO>NCT00732420</DOCNO>
	<brief_summary>To determine dose topotecan safely give daily pazopanib .</brief_summary>
	<brief_title>Open-label Study Topotecan Pazopanib Advanced Solid Tumors</brief_title>
	<detailed_description>A Phase I Open-label Study Safety , Tolerability , Pharmacokinetics Two Schedules Oral Topotecan combination Pazopanib Subjects Advanced Solid Tumors</detailed_description>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Inclusion Criteria sign , write informed consent . least 18 year age . ECOG performance status 0 1 . Subjects must histologically cytologically confirm diagnosis advance cancer solid tumor malignancy relapse refractory standard therapy establish therapy . able swallow retain oral medication . female eligible enter participate study provide adequate establish contraception practice . Exclusion Criteria chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) receive investigational drug within 30 day 5 halflives ( whichever longer ) . receive prior treatment pazopanib/investigational antiangiogenic compound . presence uncontrolled infection . pregnant lactating . poorly control hypertension ( SBP ? 140 mmHg , DBP ? 90 mmHg . Class III IV heart failure define New York Heart Association ( NYHA ) functional classification system . arterial thrombus , myocardial infarction , admission unstable angina , uncontrolled symptomatic arrhythmia , cardiac angioplasty , stenting within last 6 month . unresolved bowel obstruction diarrhea ? Grade 1. receive allogeneic bone marrow transplant . know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate pazopanib topotecan . serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , obtain informed consent compliance study . psychological , familial , sociological , geographical condition permit compliance protocol . clinical history , current alcohol illicit drug use , judgment investigator , would interfere subject 's ability comply dose schedule protocolspecified evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>pazopanib</keyword>
	<keyword>Phase I</keyword>
	<keyword>topotecan</keyword>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>